You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

404 Results
Document
Mar 2019
Document
Apr 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
iBRUtinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Blog post
Alethea KewayoshDirector, Indigenous Cancer Control UnitCancer Care Ontario In February 2019, Alethea Kewayosh, director of the Indigenous Cancer...
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
iMAtinib,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
ixazomib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Document
May 2019
Drug
Other Name(s): Besponsa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2023
Document
Aug 2019
Document
Sep 2019

Pages